EP2299820A4 - Ophthalmic formulation of rho kinase inhibitor compound - Google Patents

Ophthalmic formulation of rho kinase inhibitor compound

Info

Publication number
EP2299820A4
EP2299820A4 EP09767519A EP09767519A EP2299820A4 EP 2299820 A4 EP2299820 A4 EP 2299820A4 EP 09767519 A EP09767519 A EP 09767519A EP 09767519 A EP09767519 A EP 09767519A EP 2299820 A4 EP2299820 A4 EP 2299820A4
Authority
EP
European Patent Office
Prior art keywords
kinase inhibitor
inhibitor compound
rho kinase
ophthalmic formulation
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09767519A
Other languages
German (de)
French (fr)
Other versions
EP2299820A1 (en
Inventor
Lori Richards
Christopher S Crean
Ward M Peterson
Leo Trevino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of EP2299820A1 publication Critical patent/EP2299820A1/en
Publication of EP2299820A4 publication Critical patent/EP2299820A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP09767519A 2008-06-18 2009-06-11 Ophthalmic formulation of rho kinase inhibitor compound Withdrawn EP2299820A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7351908P 2008-06-18 2008-06-18
PCT/US2009/047108 WO2009155209A1 (en) 2008-06-18 2009-06-11 Ophthalmic formulation of rho kinase inhibitor compound

Publications (2)

Publication Number Publication Date
EP2299820A1 EP2299820A1 (en) 2011-03-30
EP2299820A4 true EP2299820A4 (en) 2012-11-14

Family

ID=41434400

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09767519A Withdrawn EP2299820A4 (en) 2008-06-18 2009-06-11 Ophthalmic formulation of rho kinase inhibitor compound

Country Status (3)

Country Link
EP (1) EP2299820A4 (en)
JP (1) JP2011524912A (en)
WO (1) WO2009155209A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130095263A (en) * 2010-07-27 2013-08-27 인스파이어 파마슈티컬스 인코퍼레이티드 Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
US20210353642A1 (en) * 2018-10-02 2021-11-18 Case Western Reserve University Compounds for treating myelin related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20070149548A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100383140C (en) * 2002-09-12 2008-04-23 麒麟麦酒株式会社 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
CN1863779B (en) * 2003-10-15 2010-05-05 宇部兴产株式会社 Novel indazole derivative
US20050272851A1 (en) * 2004-06-04 2005-12-08 Xerox Corporation Wax emulsion for emulsion aggregation toner

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20070149548A1 (en) * 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009155209A1 *

Also Published As

Publication number Publication date
JP2011524912A (en) 2011-09-08
EP2299820A1 (en) 2011-03-30
WO2009155209A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
HK1259148A1 (en) Compounds useful as inhibitors of atr kinase
ZA201204136B (en) Pteridinones as inhibitors of polo-like kinase
IL213906A0 (en) Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
HK1161260A1 (en) Compounds useful as inhibitors of atr kinase atr
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2378875A4 (en) Cell-permeant peptide-based inhibitor of kinases
EP2406236A4 (en) Rho kinase inhibitors
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
IL208716B (en) Phosphorus derivatives as kinase inhibitors
EP2336123A4 (en) Heterocyclic compound as protein kinase inhibitor
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
IL213464A0 (en) Kinase inhibitor compounds
EP2234618A4 (en) Benzopyrans and analogs as rho kinase inhibitors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
WO2008036459A8 (en) Inhibitors of rho kinase
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2470183A4 (en) Heterocyclic amide compounds as protein kinase inhibitors
EP2323659A4 (en) Compounds useful as inhibitors of protein kinases
IL223131A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2231152A4 (en) Thienopyranones as kinase inhibitors
EP2299820A4 (en) Ophthalmic formulation of rho kinase inhibitor compound

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121011

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20121005BHEP

Ipc: A61K 31/4545 20060101ALI20121005BHEP

Ipc: A61K 31/454 20060101ALI20121005BHEP

Ipc: A61K 31/4725 20060101ALI20121005BHEP

Ipc: A61K 31/416 20060101ALI20121005BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130511